Sisyphus and translational stroke research.
After more than 1000 failures, we know that our methods for translating effective stroke treatments from the laboratory to the clinic do not work. New preclinical and clinical approaches conceived outside of the current paradigm exist and should be carefully considered. Now, Tymianski and colleagues report on results obtained during translation of a new neuroprotectant.
Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. lydenp@cshs.org
Patrick
P
Lyden
Paul
P
Lapchak
D000818:Animals; D001681:Biological Assay; D002545:Brain Ischemia / Q000628:therapy; D002626:Chemistry, Pharmaceutical / Q000379:methods; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use; D020521:Stroke / Q000628:therapy*; D057170:Translational Research, Biomedical / Q000379:methods*; D016896:Treatment Outcome
D018696:Neuroprotective Agents